Literature DB >> 35260841

Tirzepatide for diabetes: on track to SURPASS current therapy.

Filipe A Moura1, Benjamin M Scirica1, Christian T Ruff2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35260841     DOI： 10.1038/s41591-022-01733-2

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Authors:  Stefano Del Prato; Steven E Kahn; Imre Pavo; Govinda J Weerakkody; Zhengyu Yang; John Doupis; Diego Aizenberg; Alan G Wynne; Jeffrey S Riesmeyer; Robert J Heine; Russell J Wiese
Journal:  Lancet       Date:  2021-10-18       Impact factor: 79.321

2.  Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.

Authors:  Naveed Sattar; Sophia Zoungas; Darren K McGuire; Imre Pavo; Govinda J Weerakkody; Hiroshi Nishiyama; Russell J Wiese
Journal:  Nat Med       Date:  2022-02-24       Impact factor: 53.440

Review 3.  The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.

Authors:  Michael A Nauck; Daniel R Quast; Jakob Wefers; Andreas F H Pfeiffer
Journal:  Diabetes Obes Metab       Date:  2021-09       Impact factor: 6.577
  3 in total
  1 in total

Review 1.  Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.

Authors:  Vivek P Chavda; Jinal Ajabiya; Divya Teli; Joanna Bojarska; Vasso Apostolopoulos
Journal:  Molecules       Date:  2022-07-05       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.